Previous close | 9.18 |
Open | 9.46 |
Bid | 8.96 x N/A |
Ask | 9.82 x N/A |
Day's range | 9.46 - 9.46 |
52-week range | 3.62 - 30.30 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 07 Nov 2024 - 11 Nov 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026 WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company’s Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to inter
WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDates: September 9-11, 2024A pre-recorded presentation will be made available on Monday, September 9, 2024 at 7:00 AM ET. Stifel 2024 Virtual Immunology and Inflammation SummitFireside Chat Date
Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal OfficerCash on hand of approximately $93.4 million as of June 30, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 202